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Inherited mtDNA diseases transmit maternally and
cause severe phenotypes. Currently, there is no
effective therapy or genetic screens for these dis-
eases; however, nuclear genome transfer between
patients’ and healthy eggs to replace mutant
mtDNAs holds promises. Considering that a polar
body contains few mitochondria and shares the
same genomic material as an oocyte, we perform
polar body transfer to prevent the transmission of
mtDNA variants. We compare the effects of different
types of germline genome transfer, including spin-
dle-chromosome transfer, pronuclear transfer, and
first and second polar body transfer, in mice. Recon-
structed embryos support normal fertilization and
produce live offspring. Importantly, genetic analysis
confirms that the F1 generation from polar body
transfer possesses minimal donor mtDNA carryover
compared to the F1 generation from other pro-
cedures. Moreover, the mtDNA genotype remains
stable in F2 progeny after polar body transfer. Our
preclinical model demonstrates polar body transfer
has great potential to prevent inherited mtDNA
diseases.INTRODUCTION
A common condition caused by maternally inherited mitochon-
drial diseases is heteroplasmy, which is a mixture of mutated
and wild-type mtDNA inside the cell. Clinical phenotypes are
generally related to the heteroplasmy level, i.e., the proportion
of pathogenic mtDNA mutations in affected tissues. In humans,
if the mutation load is over a threshold (60% in most cases),
individuals may develop severe systemic diseases such as neu-ropathy, liver failure, myopathy, cardiomyopathy, and sensory
deficit (Brown et al., 2006; Schon et al., 2012).
The frequency of pathogenic mtDNAmutations has been esti-
mated at 1 in 200 in the general population, whereas the preva-
lence of mtDNA diseases is at least 1 in 10,000 individuals (Chin-
nery et al., 2012). Currently, inherited mitochondrial diseases
are incurable and the treatments available are predominantly
supportive. Genetic counseling, along with preimplantation
genetic diagnosis (PGD) may not be useful for detecting the
extent of mtDNA heteroplasmy (Bredenoord et al., 2008; Stef-
fann et al., 2006), owing to certain aspects of mitochondrial ge-
netics such as maternal inheritance (Giles et al., 1980; Hutchison
et al., 1974), ‘‘bottleneck’’ segregation (Cao et al., 2007; Cree
et al., 2008; Wai et al., 2008), and selective replication (Fan et al.,
2008; Meirelles and Smith, 1997; Stewart et al., 2008). Therefore,
new approaches are necessary to prevent the transmission of
inherited mtDNA variants from mother to child.
With the increasing interest in developing new strategies to
prevent mtDNA diseases, the UK Human Fertilization and
Embryology Authority (HFEA) and the US Food and Drug Admin-
istration (FDA) have been evaluating new research approaches
such as mitochondrial replacement (MR) between oocytes to
treat patients (FDA, 2014; HFEA, 2012). MR therapy involves
transferring the nuclear genome from a patient’s egg into an
enucleated healthy egg with normal mtDNA and has been facil-
itated by a series of advances. Early studies involving pronuclear
transfer (PNT) between mouse zygotes showed that the mtDNA-
related phenotypes were corrected in a mouse model (Sato
et al., 2005). In humans, PNT between zygotes has shown minor
donor mtDNA carryover in early embryos (Craven et al., 2010).
However, in the same PNT mouse study, PNT-generated mice,
though free of mtDNA-related phenotypes, still had 5%–44%
heteroplasmy level at day 300 after birth (Sato et al., 2005),
largely because abundant mtDNA molecules amplify and aggre-
gate after fertilization and contaminate the transplanted pronu-
clei with cytoplasm leading to carryover (Cao et al., 2007; Santos
et al., 2006). In addition, PNT requires fertilizing both the donor
and the recipient oocytes, which results in discarding half ofCell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc. 1591
Figure 1. Schematic Charts of Experimental Design
(A) Diagram outlining PB1 genome transfer and spindle-chromosome transfer to exchange mtDNA genotypes. Oocytes were obtained from mice strains with
different mitochondria genotyoes (red and blue). PB1 and spindle-chromosome complex from donor oocyte were transferred into enucleated recipient oocyte.
After exchange, PB1 transfer-generated offspring and spindle transfer-generated offspring were delivered.
(B) Diagram outlining PB2 genome transfer and pronuclear transfer to exchange mtDNA genotypes. Zygotes were obtained from two mice strains with different
mitochondria genotypes (red and blue). PB2 and pronuclei were transplanted to half-enucleated and enucleated recipient zygotes, respectively. Then offspring
were delivered from foster mothers. See also Table S1.the embryos during manipulation. Recent experiments have
used spindle-chromosome transfer (ST) between mature
oocytes to eliminate inherited mtDNA variants in nonhuman pri-
mate and early human embryos (Paull et al., 2013; Tachibana
et al., 2009, 2013). The results showed minimal carryover in pri-
mate offspring and human embryonic stem cells. However,
because the spindle apparatus is sensitive (Kitajima et al.,
2011), the outcome of spindle manipulation is operator depen-
dent. Moreover, previous reports on in vitro mtDNA analysis
of PNT- and ST-treated human cells may not accurately reflect
the in vivo mtDNA inheritance and segregation landscape in
live offspring.
Based on these considerations, we hypothesized that the first
and second polar bodies (PB1 and PB2) could be efficient and
feasible donor germ cells for the complete replacement of
mtDNA genotype (Figures 1A and 1B). PB1 and PB2 are small1592 Cell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc.germ cells that divide by meiosis. The mammalian primary
oocyte extrudes a diploid PB1 before ovulation. After fertilization
with a sperm cell, the oocyte emits a haploid PB2 and the re-
maining fertilized zygote contains a haploid female pronucleus
(FPN) andmale pronucleus (MPN). Increasing evidence in recent
decades shows that PB1 and PB2 include the same genetic
material and developmental potential as their counterparts
inside the ooplasm (Bieber et al., 1981; Hino et al., 2013;
Wakayama and Yanagimachi, 1998; Wakayama et al., 2007,
1997). Moreover, a recent study using MALBAC-based single-
cell technology showed that PB1 and PB2 faithfully possess
the same genome settings as the sister nuclei of oocyte (Hou
et al., 2013).
Using polar bodies (PBs) provides certain advantages. First,
due to oocyte-biased inheritance of mitochondria and the rela-
tively small size of PBs, PB1 and PB2 contain very few cellular
organelles, such as mitochondria, and are composed almost
entirely of chromatids (Dalton and Carroll, 2013; Piko´ and Tay-
lor, 1987). Thus, a minimal carryover of donor (patient) mtDNA
genotype is expected in the reconstituted embryos and
offspring produced by PB transfer. Second, enveloped with a
cellular membrane, PB1 and PB2 can be easily visualized and
handled in a micropipette without chromosome loss (Maro
et al., 1986). Third, if the transfer of PBs and their sister nuclei,
spindle or pronuclear nuclear, could be used together in each
individual donor egg, this process would reduce by half the
number of donor oocytes used and greatly increase the effi-
ciency of MR.
Here, we report that PB1 and PB2 can be used as donor ge-
nomes to replace the genome of recipient eggs as an efficient
approach of MR in a mouse model. We present a comparative
analysis of using pronuclear, spindle, PB1 and PB2 transfer to
generate mouse progeny to establish preclinical models for
novel therapies (Figures 1A and 1B). We first compared mito-
chondrial distribution in oocytes and PBs. We then investigated
the developmental outcomes and donor mtDNA carryovers in
the F1 and F2 offspring after MR. We also conducted additional
array-based genomic studies between human eggs and PBs
to extend the possibilities of polar body genome transfer for
clinical translations.
RESULTS
PBs Contain Fewer Mitochondria Than Their
Sister Oocyte
For minimal carryover of mtDNA variants after MR therapy, it is
crucial to isolate nuclear complexes with minimal donor mtDNA
content. We hypothesized that PBs have fewer mitochondria
than their counterparts, the spindle-chromosome complexes
and pronuclei in oocytes and zygotes, respectively. To test
that, we tested the mitochondria content in oocytes and zygotes
via immunofluorescence staining and digital quantitative PCR.
We first stained B6D2F1 (BDF1) mouse oocytes and zygotes
with Hoechst and MitoTracker to visualize the nuclear DNA
and mitochondria via confocal microscopy with z stacked
images. As expected, PB1 contained few mitochondria and
almost no visible mitochondria in some cases (Figure 2A). The
spindle-chromosome complex was surrounded by amounts of
mitochondria in some oocytes (Figure 2A). Corroborating recent
findings, mitochondria aggregated around the spindle during
oocyte maturation and were then distributed universally
throughout the MII oocyte (Dalton and Carroll, 2013). We explain
this behavior through the notion that the spindle-chromosome
complex requires ATP to reassemble, migrate, and divide during
meiosis, which resulted in the surrounding mitochondria aggre-
gation. Nuclear DNA staining showed that PB1 and oocyte share
similar chromosome morphologies (Figure 2A). Next, we de-
tected the mitochondrial distribution in zygotes. PB2 contained
fewmitochondria, whereas in zygotes, mitochondria were abun-
dant and distributed homogeneously (Figure 2B). This finding
correlated with previous reports, wherein zygotic activation
induced mtDNA aggregation (Cao et al., 2007; Santos et al.,
2006). Addtionally, DNA staining exhibited the same pronucleus
morphology in PB2 (Figure 2B).Next, through higher magnification of isolated karyoplasts
from PB1, spindle-chromosome complex, PB2 and pronuclei,
PBs were confirmed to contain fewer mitochondrial molecules
than their counterparts (Figures 2C and S1A available online).
The fluorescence intensity of PBs was significantly lower than
that of the spindle-chromosome complex or the pronuclei
(p < 0.0001, n = 10 per group) (Figures 2D and S1A). Although
it is technically feasible to reduce mitochondria content by
isolating karyoplasts with less cytoplasm, the chromosome
might be lost because the spindle-chromosome complex does
not include a nuclear membrane. In contrast, enveloped with
a cellular membrane, PB1s were easier to isolate without chro-
mosome loss.
To further investigate the mitochondrial content, we employed
chip-based digital PCR to estimate the mtDNA copy number in
germline karyoplasts (Figures 2E and S1B). Based on PCR
amplification of single-template molecules, digital PCR is a
precise analytical technique for quantifying nucleic acid samples
without a standard curve for reference, and the number of
positive and negative PCR reactions was used to count the
number of target mtDNA molecules (Sanders et al., 2011; Taylor
et al., 2014; Vogelstein and Kinzler, 1999). In general, PB1 con-
tained 359molecules on average (n = 80), whichwas significantly
lower than the spindle complex (2,318, n = 32) (p < 0.0001)
(Figures 2E, S1B, and S1C). We also detected significantly fewer
mtDNA molecules in PB2 (1,092 on average, n = 70), than in the
pronuclei (34,392 on average, n = 39) (p < 0.0001) (Figures 2E,
S1B, and S1C).
Taken together, these results suggest a biased mitochondrial
inheritance during meiosis, resulting in the majority of mitochon-
dria being retained in the oocyte, and few mitochondria being
extruded to the PBs. Hence, we expect that genome transfer
from PB1 and PB2 can be achieved with minimal mitochondrial
DNA carryover from the donor.
Mitochondrial Replacement via PB1 Genome Transfer
and Spindle-Chromosome Transfer
We examined the feasibility and efficiency of PB1 genome trans-
fer (PB1T) for replacing the mitochondrial genotype in mouse
oocytes with a different mtDNA origin. The mtDNA of NZW/
LacJ and BDF1 mice comes from normal inbred mice but differs
by three nucleotides (Table S1). We hypothesized that each
donor oocyte offered two nuclear genome sources for mitochon-
drial replacement (MR): PB1 and the spindle-chromosome com-
plex. We conducted a PB1T and then a ST between oocytes.
Prior to nuclear transfer, we detected the cytoskeleton and
nuclear integrity of PB1. BDF1 oocytes with live PB1 were
fixed and analyzed by labeling with anti-a-tubulin antibody.
PB1 contained intact microtubules that were morphologically
similar to the spindle-chromosome complex of mature oocytes
(13–16 hr after human chorionic gonadotropin (hCG) injection)
(Figures 3A and S2A). Costaining with propidium iodide (PI)
showed that chromosomes remained attached to PB1 microtu-
bules, and labeling with the DNA damage markers of phospho-
p53 and phospho-H2A.X showed no immunoreactivity, which
demonstrated the nuclear integrity of PB1 (Figures 3B, S2A,
and S2B). Furthermore, to address the concerns over ‘‘epige-
netic’’ differences between PB1 and oocyte, we performedCell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc. 1593
Figure 2. Asymmetrical Distribution of Mitochondria between Polar Bodies and Oocytes
(A) Mouse oocytes were stained for mitochondria (MitoTracker, red) and chromosomes (Hoechst, blue) and imaged by confocal microscopy with projected z
stacks. Mitochondria are distributed throughout the oocyte (top) and aggregate around the spindle (bottom) while PB1 contains far fewer mitochondria. Images
on right are high-magnification views of boxed area in middle. Scale bar, 10 mm.
(B) Mouse zygotes were stained for mitochondria (MitoTracker, red) and nucleus (Hoechst, blue) and imaged by confocal microscopy with projected z stacks.
Mitochondria are retained abundantly throughout the zygote and aggregate around the pronucleus while PB2 contains few amounts of mitochondria. Images in
right are high-magnification views of boxed area in middle. Scale bar, 10 mm.
(C) Isolated karyoplasts of PB1, spindle-chromosome complex, PB2, and pronuclei were labeled with MitoTracker and Hoechest to visualize mitochondrial
distribution in higher magnification views. Scale bar, 5 mm.
(D) The relative fluorescence intensity of isolated karyoplasts (PB1, spindle-chromsome complex, PB2, and pronuclei) was quantified and significance
was assessed using paired t test. Significant reduced intensity was detected in PB1 and PB2. ****p < 0.0001. Error bars indicate SD, with the mean value and
n = 10 per group.
(E) Quantification ofmtDNA copy number in karyoplasts was accessed by digital PCR. Significant reducedmtDNAmolecules were detected in PBs. ****p < 0.0001
(unpaired t test). Error bars indicate SD, with the mean value and n = 80, 32, 70, 39 in PB1, spindle complex, PB2T, and PN, respectively.
See also Figure S1.immunostaining with antibodies to 5-methylcytosine (5mC),
histone H3 tri-methyl K9 (H3K9me3), and histone H3 phospho
S10 (phospho H3) between oocytes and PB1s was performed
(Cantone and Fisher, 2013; Gu et al., 2010; Kota and Feil,
2010; Santos et al., 2005). PB1 exhibited very similar expression
of 5mc, H3K9me3, and phospho H3 to the oocyte chromosomes
(Figures 3C, 3D, and 3E). These imply that PB1 didn’t contain
significant ‘‘epigenetic’’ alterations compared with the oocyte1594 Cell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc.chromosomes, which favors the programming of PB1 genome
when transferred into recipient ooplasm.
We then performed PB1T and ST in oocytes to exchange the
mitochondrial genotypes. By optimizing the superovulation
timing, we collected mature NZW oocytes with a live PB1 as
the donor genome, which allowed us to isolate the spindle-chro-
mosome complex and PB1 from a single oocyte. Live PB1s, with
an intact plasma membrane, were easily visualized and isolated
Figure 3. PB1 Integrity and Mitochondrial Replacement by PB1 Genome and Spindle-Chromosome Transfer
(A) Confocal analysis of a-tubulin in PB1 and spindle-chromosome complex.
(B) Oocytes were immunofluorescently labeled with antibodies to a-tubulin and PI to visualize microtubules and chromosomes in PB1 and spindle-chromosome
complex. Right image is high-magnification view of boxed area in the left.
(C–E) Representative confocal images of oocytes with PB1 costained with antibodies to (green) 5mc (C), H3K9me3 (D), phospho-H3 (E) and PI (red).
(F–G) PB1 was isolated from donor oocyte and then transferred into recipient oocyte to exchange mitochondria genotypes (F). After PB1 transfer, spindle-
chromosome complex was isolated from donor and transferred to recipient oocyte (G). Experimental schemes (left) and micromanipulation images (right) are
shown.
Scale bar, 10 mm. See also Figure S2 and Movies S1 and S2.in a micropipette (Figure 3F and Movie S1). In total, 25 (92.6%)
live PB1s were retrieved from 27 oocytes (13–16 hr post-hCG),
and then transplanted into the enucleated BDF1 oocytes (Fig-
ure 3F, Table S2, and Movie S1). Immediately following the
PB1 transfer, the donor oocytes were used for ST. Twenty-seven
spindle-chromosome complexes were collected and subse-
quently fused to enucleated recipient BDF1 oocytes using
HVJ-E (inactivated Hemagglutinating Virus of Japan envelope)
protein (Figure 3G, Table S2, and Movie S2). The survival rates
after nuclear transfer were very high in both groups; 19 (76.0%)out of 25 and 24 (88.9%) out of 27 reconstructed oocytes were
collected after PB1T and ST, respectively (Table S2).
We concluded that a single oocyte could offer two donor
genome sources for an efficient MR procedure. Nuclear genome
transfer from 27 donor oocytes yielded 43 mitochondria-
replaced oocytes, which almost doubled the MR success rates.
We demonstrated that, assuming MR therapy was used in
clinical settings for women that carried mutant mtDNA, PB1T,
together with ST would reduce the necessary donor (patient)
oocytes by one-half needed and enhance the efficiency.Cell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc. 1595
Figure 4. Integrity of PB2 and Mitochondrial Replacement by PB2 and Pronuclear Transfer
(A) Zygotes were immunofluorescently labeled with antibodies to lamin B1 and PI to visualize nuclear membrane and chromosomes in PB2 and pronuclei.
(B–D) Representative confocal images of zygotes with PB2 costained with antibodies to (green) 5mc (B), H3K9me3 (C), acetyl-H3 (D) and PI (red).
(E and F) PB2 was isolated from donor zygote and transplanted to female pronucleus (FPN)-enucleated recipient (E). Then pronuclei were isolated from donor
zygote and transferred to enucleated recipient zygote (F). Experimental schemes are shown on left and micromanipulation images are shown on the right.
Scale bar, 10 mm. See also Figure S3, Movies S3 and S4.Mitochondrial Replacement via PB2 Genome Transfer
and Pronuclear Transfer
We next investigated the potential for using second polar body
transfer (PB2T), together with pronuclear transfer (PNT) as mito-
chondrial replacement (MR) approaches.
Initially, we detected the nuclear membrane integrity of PB2
and its sister FPN by costaining with antibody to Lamin B1 and
PI (Goldberg et al., 2008; Houliston et al., 1988; Link et al.,
2013). PB2 contained an almost identical envelope and pronu-
cleus morphology to FPN (Figures 4A and S3). Immunostaining
with phospho-p53 and phospho-H2A.X showed no DNA dam-
age in PB2 (Figure S2B). We also colabeled Lamin B1 and PI
to visualize the membrane morphology and pronucleus sizes at
different pronuclear stages (PN stage, PN0-PN4) (Figure S3).
At PN0-PN2, the size and lamin expression of PB2 nucleus1596 Cell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc.were similar to those of the FPN (Figure S3). After the PN3 stage,
the FPN was significantly larger than PB2 (Figure S3). To syn-
chronize the nucleus size of the donor and the recipient, we
reasoned that the recipient zygote at PN0-PN2 would be more
appropriate for PB2 programming (Figure S3).
We then compared the ‘‘epigenetic’’ status, DNA methylation,
and histone modification status of the PB2 genome and its
sister FPN by labeling zygotes with anti-5mc, anti-H3K9me3,
and anti-acetyl-H3 antibodies (Figures 4B, 4C, and 4D)(Cantone
and Fisher, 2013). We observed 5-mc and H3K9me3 in the
FPN but not in the MPN (Figures 4B and 4C), which indicated
that the maternal genome has a protective mechanism against
demethylation (Cantone and Fisher, 2013; van der Heijden
et al., 2005; Liu et al., 2004; Santos et al., 2005). The fluorescent
signals for the 5mc, H3K9me3, and acetyl-H3 were clear in PB2,
Figure 5. Developmental Outcomes after Mitochondrial Replacement
(A) Overall in vitro and in vivo development outcomes after mitochondrial replacement in each group. IVF is intact control group without nuclear transfer.
(B) Developmental potential of reconstructed oocytes to blastocyst stage and offspring birth after mitochondrial replacement via PB1T, ST, PB2T, and PNT.
(C) Appearance of reconstructed embryos (zygote at 6 hr postmanipulation) after mitochondrial replacement, pups at birth, and F1 and F2 adulthood offspring.
(D) Bar diagram presenting body weights (mean ± SD) of pups (n = PB1T, 6; ST, 8; PB2T, 6; and PNT, 7) and their placenta weights (mean ± SD) produced by
mitochondrial replacement.
See also Figure S4, Table S2.which suggests that it shares similar chromatin pattern to the
FPN (Figures 4B, 4C, and 4D). The similar ‘‘epigenetic’’ patterns
in PB2 and the FPN indicate that PB2 could be used as a substi-
tute for the FPN.
We then conducted PB2 and pronuclei transfers between
the donor and the recipient zygotes. After collecting the donor
zygotes, PB2was isolated in amicropipette and then transferred
into a half-enucleated recipient zygote at the PN0-PN2 stage
(Figure 4E and Movie S3). The FPN of the recipient zygote was
enucleated for PB2T, and the MPN remained (Movie S3). The
haploid set of female genomes inside PB2 was transplanted
into FPN-enucleated recipient zygotes (Figure 4E and Movie
S3). In total, 30 PB2s (retrieved from 30 zygotes) was transferred
into the recipients, and 28 (93.3%) survived the manipulation
(Table S2). Next, 19 pronuclei karyoplasts (retrieved from
30 zygotes) from donor zygotes were transferred to enucleated
recipient zygotes (Figure 4F and Movie S4). Sixteen out of 19
(84.2%) PNT-generated reconstructed zygotes survived aftermanipulation (Table S2). These results demonstrated that PB2
can be readily manipulated and used for MR treatment in an
efficient way.
Developmental Potential after Mitochondrial
Replacement
To further examine the efficiency of mitochondrial replacement
treatment by different germline genome (PB1, spindle, PB2,
and pronuclear) transfer techniques, we compared the develop-
mental competence of reconstituted embryos both in vitro and
in vivo.
We introduced sperm cells into reconstructed oocytes after
PB1T and ST via in vitro fertilization (IVF), and the fertilization
rates were calculated for both groups: 17 out of 19 (89.5%)
fertilized PB1T-generated oocytes and 21 out of 24 (87.5%)
fertilized ST-oocytes were obtained. The PB1T-generated
embryos cleaved at a 94% frequency, and 87.5% developed
into blastocysts (Figures 5A, 5B, S4, and Table S2). The resultsCell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc. 1597
were similar for ST-generated embryos; 100% of ST-oocytes
cleaved and 85.7% developed to blastocysts (Figures 5A, 5B,
and S4, and Table S2). These indicate that PB1 maintains a
similar developmental potential to its sister spindle-chromo-
some complex. The results were comparable with the intact
oocyte IVF group (p > 0.05). For PB2T and PNT, the cleavage
rates were similar (96.4% and 100%, respectively), whereas
the PNT-embryos yielded higher blastocyst rates (55.5% and
81.3%, respectively). Next, we tested in vivo developmental
competence by transferring these MR-treated blastocysts into
pseudopregnant mothers. Six living PB1T-generated F1 pups
(42.8%) out of 14 transferred blastocysts were delivered from
two recipients, which is similar to the ST-generated embryos (8
living pups [44.4%]) out of 18 blastocysts from 3 recipients) (p
> 0.05) (Figures 5B and 5C, and Table S2). In the PB2T and
PNT groups, 6 (40%) and 7 (53.8%) living F1 pupswere delivered
out of 15 and 13 blastocysts, respectively (Figures 5B and 5C,
and Table S2). All living pupswere born healthy and respired nor-
mally. The birth rates of MR-newborns were comparable to
those of the intact control group (p > 0.05) (Figure 5B and Table
S2). These results demonstrate that MR therapy, including PB
transfer, did not compromise the developmental competence
and produced living progeny from each of the four nuclear
transfer techniques. In addition, the birth weights and placenta
weights of all MR-generated pups were in the normal range in
a manner reminiscent of the intact group (p > 0.05), which
indicates that the MR treatment did not produce overgrowth
phenotype (Figure 5D).
Overall, these results demonstrated that the reconstructed
embryos produced using PB1 and PB2 were suitable for onward
development at rates similar to the ST- and PNT-generated
embryos as well as the controls.
mtDNA Carryover Analysis through Pyrosequencing
To determine the mtDNA carryover in mice delivered after MR
treatment, we adopted the high-throughput pyrosequencing
method, which has a detection threshold of approximately 1%,
100% specificity, and 100% sensitivity, to examine the level
of heteroplasmy (Blakely et al., 2013; White et al., 2005). We
exploited the C9461T SNP variant in the ND3 gene between
the donor and the recipient to distinguish the mtDNA origins
of MR-infants (Figures 6A and 6B and Table S1). Thus, where
heteroplasmy is present, the proportion of genome donor’s
mtDNA would be detected.
We first quantified the heteroplasmy proportions in the tail
tips and important organs of the F1 generation infants after birth.
The male infants were sacrificed to detect the levels of mtDNA
variants in the important organs, namely the brain, heart, lungs,
liver, and kidneys. The female infants were allocated to foster
mothers and their tail tips were used to monitor mtDNA hetero-
plasmy. We compared the level of heterolasmy for the four
MR-treatment groups by collecting the data on the proportion
of donor mtDNA in the tail tissues of fostering infants and brain
tissues of sacrificed infants. The mean heteroplasmy level for
all (n = 6) PB1T-generated infants was undetectable (Figures
6C and S5). The mean heteroplasmy level for the ST-generated
infants was at 5.5% ± 1.4% (mean ± SD, n = 8), which is sig-
nificantly higher than the PB1T-generated group (p = 0.0007)1598 Cell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc.(Figures 6C and S5). The PB2T infants had 1.7% ± 2.8% (n =
6) mtDNA carryover on average, wheras the PNT infants had
high level of 23.7% ± 11.1% on average (n = 7), which is signifi-
cantly higher than the PB2T group (p = 0.0012) (Figures 6C and
S5). These results are consistent with the findings that PBs
contain far fewer mtDNA molecules than do spindle and pronu-
clei karyoplasts.
We surveyed the mtDNA variant levels in important organs
and tissues (brain, heart, lungs, liver, and kidneys) in the F1
generation mice, which require more energy (Spreadsheet
S1). As expected, the PB1T-generated infants exhibited unde-
tectable carryover (0%) in all tissues (n = 15) (Figures 6E and
S5). This confirms that PB1T can reduce the transmission of
donor mtDNA to the lowest level. The level of mtDNA hetero-
plasmy in all biopsied tissues from ST-generated infants was
detected at a medium to low level (range 0%–6.88%, n = 20)
(Figures 6F and S5). The PNT-generated infants had sig-
nificantly high levels of heteroplasmy; all biopsied tissues
included detectable levels of mtDNA variants (range 5.55%
39.8%, n = 15) (Figures 6H and S5). In contrast, the levels
mtDNA variants were undetectable in all biopysed tissues
(n = 10) of two PB2T-generated infants (Figures 6G and S5).
Only one PB2T-treated infant exhibited a dectable level of
heteroplasmy (range 3.08%–3.62%, n = 5) (Figures 6G and
S5). In addition, the heteroplasmy level between the organs
investigated was consistent; thus, if mtDNA carryover was de-
tected in one mouse, the variations were consistent between
the important organs investigated.
In a previous study of ST-treated primates, a significant
increase (14.2% and 16.1%) of donor mtDNA carryover was
detected in biopsied oocytes from the pups’ ovaries, indicating
that heteroplasmic mtDNA may undergo selective amplification
during germline development, and transmit it to the next gener-
ation of offspring (Tachibana et al., 2009). To address this
concern, we mated female F1 generation progeny with male
C57 mice and detected whether the mtDNA genotype remained
stable in the next F2 generation (Figures 6D, 6I, and S5 and
Spreadsheet S1). The level of heteroplasmy in the toe tips of
the F2-PB1T mice (n = 16) was undetectable (0%), which is
significantly lower than in the F2-ST mice (7.1% ± 6.8%, n =
28) (p < 0.0001) (Figures 6D, 6I, and S5). This indicates that
PB1 genome transfer can yield undetectable levels of mtDNA
heteroplasmy in pups over generations. The F2-PNT mice
exhibited 22.1% ± 18.7% carryover (n = 21), whereas the
F2-PB2T group contained significantly lower mtDNA variants
(2.9% ± 4.3%, n = 21) (p < 0.0001)(Figures 6D, 6I, and S5). Inter-
estingly, for females with high levels of mtDNA heteroplasmy
(such as in the PNT group) the predilection to maintain mtDNA
heteroplasmy remains. And for females with undetectable
level of mtDNA heteroplasmy (such as in the PB1TGroup), nomi-
nority mtDNA content was detected in the F2 pups. However,
when the level of mtDNA heteroplasmy was around the median
(approximately 10%), then the transmission of minority mtDNA
becomes random.
Taken together, the results strongly support the notion that
PB transfer, especially PB1T, can be efficiently used for MR
therapy and produce offspring with undetectable levels of
donor-derived mtDNA over generations.
Figure 6. mtDNA Carryover after Mitochondrial Replacement
(A) mtDNA sequence variant (m. 9461C > T) in ND3 gene used for pyrosequencing to detect mtDNA heteroplasmy level.
(B) Sequence pyrogram for mtDNA variant (m.9461C > T) in donor (left) and recipient (right) oocytes.
(C and D) Heteroplasmy quantification of pups of F1 (C) and F2 generation (D) by pyrosequencing. Both F1 and F2 PB1T-generated infants showed undetectable
mtDNA carryover, significantly lower than ST group. F1 and F2 PB2T-generated pups also showed significantly fewer mtDNA carryover than PNT group.
Asterisks indicated significant changes with p value presented (Mann-Whitney test). Error bar indicate SD, with the mean value and n number shown.
(E–H) Heteroplasmy levels of detected tissues from F1 pups produced by PB1 transfer (PB1T, E), spindle transfer (ST, F), PB2 transfer (PB2T, G), and pronuclear
transfer (PNT, H). Brain, heart, lung, liver and kidney tissues were sampled to detect the transmission of heteroplasmy level after mitochondrial replacement.
(I) Heteroplasmy levels of all F2 pups in PB1T,ST, PB2T and PNT groups.
See also Figure S5, Table S1, and Spreadsheet S1.Genomic Integrity of Human Polar Bodies
Is Confirmed by aCGH
To extend our findings in mouse models, we performed array
comparative genomic hybridization (aCGH) to detect genomic
aberrations between PB1 and its counterpart, the spindle-chro-
mosome complex, in a human MII oocyte, PB2 and the femalepronucleus in a human zygote at the single-cell level. Immunos-
tainting with the DNA damagemarker of phospho-p53 and phos-
pho-H2A.X showed no signal in both human PB1s and PB2s
(Figures S2B). We isolated PB1 from an MII oocyte and the spin-
dle-chromosome complex in its cytoplasm. The single-cell
aCGH analysis confirmed a similar chromosome copy numberCell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc. 1599
(legend on next page)
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between PB1 and the spindle-chromosome complex. Both had
a diploid genome and no alterations were detected (Figures
7A, 7B, S6A, and S6B). Likewise, the aCGH analysis of a zygote
confirmed the fact that PB2 had the same haploid genome as
female pronucleus and no meaningful genomic alterations
were detected (Figures 7C, 7D, S6C, and S6D). Our findings
were consistent with previous reports that the PB and oocyte
share the same genomic landscape (Christopikou et al., 2013;
Geraedts et al., 2011; Hou et al., 2013), hence the nuclear trans-
fer between the PB and oocyte can be readily performed and
paves the way for PB-based MR therapy in a clinical setting.
DISCUSSION
Our data present evidence of efficient mitochondrial genotype
exchanges using polar bodies to prevent the transmission of
mtDNA variants. PB1T produces undetectable level of mtDNA
heteroplasmy in all offspring. The easy visualization and efficient
manipulation of PB1 and live birth thereafter confirms the feasi-
bility of PB1T as an MR treatment. The ST-generated live
offspring had low to median level of donor mtDNA variants. For
ST-generated mice, the level of mtDNA heteroplasmy in our ex-
periments was greater than in previous reports on ST-generated
embryonic stem cells and primate offspring (Paull et al., 2013;
Tachibana et al., 2009, 2013). This discrepancy is largely
because the spindle-chromosome complex didn’t have a mem-
brane, and to prevent chromosome loss during manipulation,
certain volume of cytoplasm is retained. To achieve minimal
carryover, a higher-resolution microtubule birefringence should
be used to visualize the spindle apparatus. It should also be
noted that the human spindle complex is smaller than the mouse
counterpart; thus, human ST resulted in less variant carryover.
Furthermore, ST is subject to operator-dependent factors (e.g.,
the quantity of cytoplasm aspirated and transferred to the recip-
ient, which was dependent on the individual embryologists).
In contrast, PB1 isolation and transfer can be completed in a sin-
gle step, which is similar to intracytoplasmic sperm injection
(ICSI), a routine practice in IVF settings (Movie S1).
The average mtDNA carryover in PNT-generated offspring
was the highest (23.7%), which is consistent with previous
findings that PNT treatment produced heteroplasmic progeny
(Meirelles and Smith, 1997; Sato et al., 2005). This is mainly
because zygotic activation induces mtDNA amplification around
pronuclei (Cao et al., 2007; Santos et al., 2006). In contrast,
PB2T-generated offspring harbor low or undetectable donor
mtDNA carryover, which indicates that PB2 can be used as a
FPN substitute to achieve minimal donor mtDNA variants during
MR treatment. However, the obstacle of PB2T is that, unlike
PB1, PB2 only contains a haploid set of genome, thus in our
experiments the recipient oocyte is half enucleated, and the
MFN is remained. Assuming that this technique is applicable in
the clinic, it is particularly challenging to isolate one pronucleusFigure 7. aCGH Analysis of Human Oocytes and Polar Bodies
(A–D) aCGH showed that humanMII oocyte and its adjoining PB1 (A and B), fema
landscape. No major alterations (amplifications or losses) were detected in PBs.
See also Figure S6.in human recipient oocytes, and we presume that both pronuclei
should be enucleated and then sperm cell be introduced later
in the reconstructed oocytes via IVF or ICSI.
The minimal mtDNA carryover after PB1T and PB2T is consis-
tent with the quantification results formtDNAmolecules using 3D
digital PCR. For human oocytes, it has been reported that PB1
harbors approximately ten molecules, as determined using a
computational model of mtDNA mutation analysis (Gigarel
et al., 2011). This is largely because the sizes of human PB is
significantly smaller than those of mice PB, which makes the
cytoplasm volume (and the mtDNA therein) of a human PB is
less than that of a mouse PB. In an earlier study, 1,000 mtDNA
copies on average were detected in ten human PBs (three PBs
contained almost no mtDNA copies, and four PBs included
less than 500 copies) (Steuerwald et al., 2000). The differences
and variations between the samples would be attributed to the
difference in oocyte ages, sample size, PCR accuracy, and
some unknown mtDNA dynamics that lower the mtDNA copies
in mutated oocytes. We believe that further careful assessments
of mtDNA copies in human PBs should be approached before
clinical translations.
Given that inherited mtDNA diseases are difficult to treat,
their prevention is a priority. Recently, the Nuffield Council
on Bioethics has endorsed the research concerning nuclear
transfer to prevent inherited mtDNA diseases (Nuffield Council
on Bioethics, 2012). Inherited mtDNA variant transmission is
complex because of the ‘‘bottleneck’’ at early oogenesis (Cao
et al., 2007; Cree et al., 2008; Stewart et al., 2008). And the
phenotype severity is related to a threshold effect; typically if
the mutation load is greater than 60%, severe symptoms and
higher mortality rates will appear (Brown et al., 2006; Schon
et al., 2012; Wallace and Fan, 2009). However, studies have
confirmed that even a <5% level of heteroplasmy can produce
severe diseases in humans (Ballana et al., 2008). Thus MR
should decrease donor (patient) mtDNA carryover to the least
level. Our results indicate that polar body genome transfer, espe-
cially PB1 transfer, minimized the quantity of donor (patient)
mtDNA carryover and produced offspring with an undetectable
level of heteroplasmy. An additional concern over PB transfer
is the ‘‘epigenetic’’ issue; whether PBs have the same epigenetic
landscape as their oocyte counterpart. Our results showed
no significant decrease in developmental outcomes after PB
transfer, indicating that this technique is unlikely to cause epige-
netic and imprinting defects. However, single-cell-based epige-
netic profiling will be necessary to further evaluative epigenetic
modifications at individual loci (Lorthongpanich et al., 2013).
There is an ongoing discussion on proceeding with human
clinical trials recently, and we reason it will be important to
gather more evidence from preclinical studies on the feasibility,
efficacy, and safety of MR therapy (Reinhardt et al., 2013). More-
over, careful assessments of the cost and benefit for patients,
ethical considerations, and assisted reproduction guidelinesle pronucleus of zygote and PB2 (C and D), respectively, shared same genomic
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are necessary before translating into a clinical setting. The data
presented in this paper show that MR therapy via polar body
genome transfer has the potential to prevent inherited mtDNA
diseases. The comparative analysis of different types of germ
cell transfer in a mouse model confirmed that PB1T, PB2T,
and ST could be readily used to exchangemtDNAwithout result-
ing in significant heteroplasmy level, and PB1T yield undetect-
able level of heteroplasmy over generations. Thus our mouse
model studies would represent a potential approach for prevent-
ing inherited mtDNA disorders.
EXPERIMENTAL PROCEDURES
Detailed experimental protocols are provided in the Extended Experimental
Procedures.
Mitochondrial Replacement between NZW and BDF1 Mice
Experiment 1: Mitochondrial Replacement by PB1
and Spindle-Chromosome Transfer
BDF1 and NZW females were superovulated by PMSG (5 IU) and hCG (5 IU)
injection at 48 hr apart. Transferring of PB1 of NZW donor oocyte and enucle-
ation of BDF1 recipient oocyte were done in one step with a piezo-driven
actuator (PrimeTech). Then donor spindle-chromosome complex was gently
aspirated to a pipette, exposed to the HVJ-E (CosmoBio), and transferred to
an enucleated recipient oocyte. Reconstructed oocytes were fertilized by IVF.
Experiment 2: Mitochondrial Replacement by PB2
and Pronuclear Transfer
PB2 of donor NZW zygotes was aspirated into injection pipette with a piezo-
driven actuator (PrimeTech). After exposed to the HVJ-E, PB2 was transferred
into FPN-enucleated BDF1 zygotes. Then donor zygotes were used for pronu-
clear transfer to exchange mitochondria genotypes similar to spindle transfer.
Embryos Transfer and Pups Births
After 3 days, Blastocysts were transferred to the uterus of pseudopregnant
ICR females. Sixteen days after embryos transfer, cesaerian section was per-
formed to deliver pups of F1 generation. When reached puberty, F1 females
were mated with C57 males and delivered pups of F2 generation.
Mitochondrial Distribution and Whole-Oocyte
Immunocytochemistry
Mitochondria were labeled with MitoTracker (Life Technologies) in live oocytes
and isolated karyoplasts with counterstained of Hoechst 33342 (Life Technol-
ogies). For immunocytochemistry, primary antibodies include antibodies to
a-tubulin (Sigma), lamin B1 (Abcam), H3K9me3 (Abcam), phospho H3
(Abcam), acetyl H3 (Millipore), 5mC (Abcam), phospho-H2A.X (Cell Signaling),
and phospho-p53 (Cell Signaling). Then samples were incubated overnight at
4C and then incubated with secondary antibodies. After being washed with
PBS and counterstain of nucleus chromosome with Propidium Iodide (Invitro-
gen), cells were analyzed by confocal microscopy (Leica Microsystems).
mtDNA Copy-Number Analysis
mtDNA copy-number analysis by 3D digital PCR was provided in the
Extended Experimental Procedures.
Genotyping of mtDNA Heteroplasmy Level
All F1mice were genotyped using DNA extracted from organs and tail tips. Toe
tips of F2 pups were biopsied for mtDNA analysis. The region of mice mito-
chondria genome (nucleotide position, 9201–11102) was first amplified from
the total genome. The SNP used for detecting heteroplasmy is m.9461C > T.
Single-stranded biotinylated PCR products were prepared for sequencing
by Pyrosequencing Vacuum Prep Tool (Biotage AB). Quantification of the
heteroplasmy level was achieved using allele frequency quantification (AQ)
function in PyroQ-AQ software to compare the status of nucleotides at the
relevant position (Blakely et al., 2013; White et al., 2005).1602 Cell 157, 1591–1604, June 19, 2014 ª2014 Elsevier Inc.Statistical Analysis
All statistical analyses were performed using the Prism 6.0 statistical analysis
program (GraphPad).
Paired t test was used to access fluorescence intensity. t test, chi-square
test or ANOVA was used to access mtDNA copy number, embryo develop-
ment and pups weight. Mann-Whitney test was used to access mtDNA heter-
oplasmy. The significance was set at p < 0.05 (* denotes p < 0.05, ** denotes
p < 0.01, *** denotes p < 0.001, and ****denotes p < 0.0001.).
ACCESSION NUMBERS
aCGHdata sets are available in theGene Expression Omnibus database under
the accession number GSE56676.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, six
figures, four movies, two tables, and one data file and can be found with this
article online at http://dx.doi.org/10.1016/j.cell.2014.04.042.
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